Anaemia management and mortality risk in chronic kidney disease

Nature Reviews Nephrology

Volumn 9, Issue 5, 2013, Pages 291-301

  Hörl, Walter H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ERYTHROPOIETIN; ERYTHROPOIETIN BETA; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANEMIA; CHRONIC KIDNEY DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR;

ANEMIA; BLOOD TRANSFUSION; HEMATINICS; HUMANS; IRON; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84876963613     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2013.21     Document Type: Review

References (107)

1. Xia, H. et al. Hematocrit levels and hospitalization risks in hemodialysis. J. Am. Soc. Nephrol. 10, 1309-1316 (1999).
2. Ma, J. Z. et al. Hematocrit level and associated mortality in hemodialysis patients. J. Am. Soc. Nephrol. 10, 610-619 (1999).
3. Foley, R. N. et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am. J. Kidney Dis. 28, 53-61 (1996).
4. Kliger, A. S. et al. Erythropoietic stimulating agents and quality of a patient's life: Individualizing anemia treatment. Clin. J. Am. Soc. Nephrol. 7, 354-357 (2012).
5. Locatelli, F. et al. Anaemia in haemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol. Dial. Transplant. 19, 121-132 (2004).
6. Levin, A. et al. Haemoglobin at time of referral prior to dialysis predicts survival: In association of haemoglobin with long-term outcomes. Nephrol. Dial. Transplant. 21, 370-377 (2006).
7. Levin, A. et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am. J. Kidney Dis. 34, 125-134 (1999).
8. Foley, R. N. et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 58, 1325-1335 (2000).
9. Parfrey, P. S. et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J. Am. Soc. Nephrol. 16, 2180-2189 (2005).
10. Besarab, A. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 339, 584-590 (1998).
11. Singh, A. K. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355, 2085-2098 (2006).
12. Drüeke, T. et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 355, 2071-2084 (2006).
13. Pfeffer, M. A. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019-2032 (2009).
14. Hörl, W. H. Differentiating factors between erythropoiesis- stimulating agents: An update to selection for anemia of chronic kidney disease. Drugs http://dx.doi.org/10.1007/s40265-012-0002-2.
15. Coyne, D. W. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int. 82, 235-241 (2012).
16. Fishbane, S. & Wish, J. B. A physician's perseverance uncovers problems in a key nephrology study. Kidney Int. 82, 135-137 (2012).
17. [No authors listed] Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ 300, 573-578 (1990).
18. Roger, S. D. et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomized clinical trial. J. Am. Soc. Nephrol. 15, 148-156 (2004).
19. Clement, F. M. et al. An economic evaluation of erythropoiesis agents in CKD. Am. J. Kidney Dis. 56, 1050-1061 (2010).
20. Winkelmayer, W. C. et al. Against TREATing all patients alike: Lessons from an FDA Advisory Committee Meeting. J. Am. Soc. Nephrol. 22, 1-2 (2011).
21. Skali, H. et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darbepoetin alfa: The trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation 124, 2903-2908 (2012).
22. Unger, E. F. et al. Erythropoiesis-stimulating agents - time for a reevaluation. N. Engl. J. Med. 362, 189-192 (2010).
23. McMurray, J. J. et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). Am. Heart J. 162, 748.e3-755.e3 (2011).
24. FDA:FDA Drug Safety Communication: Modified Dosing Recommendations to Improve the Safe Use of Erythropoiesis-Stimulating Agents in Chronic Kidney Disease [online], http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm (2011).
25. Manns, B. J. & Tonelli, M. The new FDA labeling for ESA-implications for patients and providers. Clin. J. Am. Soc. Nephrol. 7, 348-353 (2012).
26. Minutolo, R. et al. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients. Nephrol. Dial. Transplant. 27, 2880-2886 (2012).
27. Tsubakihara, Y. et al. High target hemoglobin with erythropoiesis stimulating agents has advantages in the renal function of non-dialysis chronic kidney disease patients. Ther. Apher. Dial. 16, 529-540 (2012).
28. Lewis, E. F. et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: A randomized trial. Clin. J. Am. Soc. Nephrol. 6, 845-855 (2011).
29. Locatelli, F. & Del Vecchio, L. Erythropoietic response to erythropoiesis-stimulating agents and outcome: Should we give up the haemoglobin target approach? Nephrol. Dial. Transplant. 26, 2069-2077 (2011).
30. Singh, A. K. What is causing the mortality in treating the anemia of chronic kidney disease: Erythropoietin dose or hemoglobin level? Curr. Opin. Nephrol. Hypertens. 19, 420-424 (2010).
31. Freburger, J. K. et al. Changing patterns of anemia management in US hemodialysis patients. Am. J. Med. 125, 906-914 (2012).
32. Himmelfarb, J. & Szczech, L. A. Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: Con. J. Am. Soc. Nephrol. 20, 1441-1443 (2009).
33. Singh, A. K. Does TREAT give the boot to ESAs in the treatment of CKD anemia? J. Am. Soc. Nephrol. 21, 2-6 (2010).
34. Weiner, D. E. & Miskulin, D. C. Anemia management in chronic kidney disease: Bursting the hemoglobin bubble. Ann. Intern. Med. 153, 53-55 (2010).
35. Singh, A. K. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: What should we do now? Am. J. Kidney Dis. 52 (6 Suppl.), S5- S13 (2008).
36. Brookhart, M. A. et al. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 303, 857-864 (2010).
37. Akizawa, T. et al. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: A randomized controlled study. Ther. Apher. Dial. 15, 431-440 (2011).
38. Palmer, S. C. et al. Meta-analysis: Erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann. Intern. Med. 153, 23-33 (2010).
39. Jing, Z. et al. Hemoglobin targets for chronic kidney disease patients with anemia: A systematic review and meta-analysis. PLoS ONE 7, e43655 (2012).
40. Winkelmayer, W. What caused excess strokes in patients randomized to darbepoetin in the trial to reduce cardiovascular events with Aranesp therapy (TREAT)?: no smoking gun. Circulation 124, 2805-2808 (2011).
41. Balasubramaniam, G. S. et al. Allosensitization rate of male patients awaiting first kidney grafts after leuko-depleted blood transfusion. Transplantation 93, 418-422 (2012).
42. Opelz, G. et al. Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation 63, 964-967 (1997).
43. Obrador, G. T. & Macdougall, I. C. Effect of red cell transfusions on future kidney transplantation. Clin. J. Am. Soc. Nephrol. http://dx.doi.org/10. 2215/CJN.00020112.
44. O'Brien, F. J. et al. Effect of perioperative blood transfusions on long term graft outcomes in renal transplant patients. Clin. Nephrol. 77, 432-437 (2012).
45. Tonelli, M. K. S. et al. Erythropoiesis-stimulating agents for anemia of chronic kidney disease: Systematic review and economic evaluation. Technology Report Number 106, Canadian Agency for Drugs and Technologies in Health [online], http://www.cadth.ca/media/pdf/459- Erythropoiesis- tr- e.pdf (2008).
46. Weiner, D. E. et al. Reducing versus discontinuing erythropoietin at high hemoglobin levels. J. Am. Soc. Nephrol. 18, 3184-3191 (2007).
47. Calvo, J. A. et al. Nadir hemoglobin levels after discontinuating of epoetin in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 5, 1621-1627 (2010).
48. Fishbane, S. & Berns, J. S. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoetin. Kidney Int. 68, 1337-1343 (2005).
49. Ebben, J. P. et al. Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations. Clin. J. Am. Soc. Nephrol. 1, 1205-1210 (2006).
50. Brunelli, S. M. et al. Association of hemoglobin variability and mortality among contemporary incident hemodialysis patients. Clin. J. Am. Soc. Nephrol. 3, 1733-1740 (2008).
51. Eckardt, K. U. et al. Hemoglobin variability does not predict mortality in European hemodialysis patients. J. Am. Soc. Nephrol. 21, 1765-1775 (2010).
52. Pérez-Ruixo, J. J. et al. Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis-stimulating agent used to treat anaemia in dialysis: A meta-analysis. Br. J. Clin. Pharmacol. 75, 15-25 (2013).
53. Pisoni, R. L. et al. Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Associations with mortality, patient characteristics, and facility practices. Am. J. Kidney Dis. 57, 266-275 (2011).
54. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. Suppl. 2, 279-335 (2012).
55. Locatelli, F. et al. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines on anaemia management in chronic kidney disease: A European Renal Best Practice (ERBP) position statement. Nephrol. Dial. Transplant. (in press).
56. Heinze, G. et al. Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: Cohort study. BMJ 339, b4018 (2009).
57. Goodkin, D. A. et al. Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J. Am. Soc. Nephrol. 20, 358-365 (2011).
58. Winearls, C. G. et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2, 1175-1178 (1986).
59. Eschbach, J. W. et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N. Engl. J. Med. 316, 73-78 (1987).
60. Eschbach, J. W. et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann. Intern. Med. 111, 992-1000 (1989).
61. Streja, E. et al. Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis. Am. J. Kidney Dis. 52, 727-736 (2008).
62. Servilla, K. S. et al. Anemia management and association of race with mortality and hospitalization in a large not for profit dialysis organization. Am. J. Kidney Dis. 54, 498-510 (2009).
63. Bradbury, B. D. et al. Effect of epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL. Clin. J. Am. Soc. Nephrol. 4, 630-637 (2009).
64. Zhang, Y. et al. Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Clin. J. Am. Soc. Nephrol. 4, 638-644 (2009).
65. Wang, O. et al. Relationship between epoetin alfa dose and mortality: findings from a marginal structural model. Clin. J. Am. Soc. Nephrol. 5, 182-188 (2010).
66. Koulouridis, I. et al. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: A metaregression analysis. Am. J. Kidney Dis. 61, 44-56 (2013).
67. Bradbury, B. D. et al. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am. J. Kidney Dis. 51, 62-70 (2008).
68. Bradbury, B. D. et al. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. Pharmocoepidemiol. Drug Saf. 18, 932-940 (2009).
69. Inrig, J. K. et al. Impact of higher hemoglobin targets on blood pressure and clinical outcomes: A secondary analysis of CHOIR. Nephrol. Dial. Transplant. 27, 3606-3614 (2012).
70. Zhang, Y. et al. Epoetin requirements predict mortality in hemodialysis patients. Am. J. Kidney Dis. 44, 866-876 (2004).
71. Regidor, D. L. et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J. Am. Soc. Nephrol. 17, 1181-1191 (2006).
72. Kilpatrick, R. et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 3, 1077-1083 (2008).
73. López-Gomez, J. et al. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int. 111, S75- S81 (2008).
74. Panichi, N. et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: Results from the RISCAVID study. Nephrol. Dial. Transplant. 26, 2641-2648 (2011).
75. Fukuma, S. et al. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: Results from a cohort study from the dialysis registry in Japan. Am. J. Kidney Dis. 59, 108-116 (2011).
76. Locatelli, F. et al. Predictors of haemoglobin levels and resistance to erythropoiesis-stimulating agents in patients treated with low-flux haemodialysis, haemofiltration and haemodiafiltration: Results of a multicentre randomized and controlled trial. Nephrol. Dial. Transplant. 27, 3594-3600 (2012).
77. Locatelli, F. et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol. Dial. Transplant. 21, 991-998 (2006).
78. Vaziri, N. D. Anemia and anemia correction: Surrogate markers or causes of morbidity in chronic kidney disease. Nat. Clin. Pract. Nephrol. 4, 436-445 (2008).
79. Bode-Böger, S. M. et al. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin 1 and constrictor prostanoids. Kidney Int. 50, 1255-1261 (1996).
80. Rodrique, M. E. et al. Relationship between eicosanoids and endothelin 1 in the pathogenesis of erythropoietin-induced hypertension in uremic rats. J. Cardiovasc. Pharmacol. 41, 388-395 (2003).
81. Barrett, J. D. et al. Erythropoietin upregulates angiotensin receptors in cultured rat vascular smooth muscle cells. J. Hypertens. 16, 1749-1757 (1998).
82. Anagnostou, A. et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc. Natl. Acad. Sci. USA 87, 5978-5982 (1990).
83. Akimoto, T. et al. Involvement of erythropoietin-induced cytosolic free calcium mobilization in activation of mitogen-activated protein kinase and DNA synthesis in vascular smooth muscle cells. J. Hypertens. 19, 193-202 (2011).
84. Stohlawetz, P. J. et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 95, 2983-2989 (2000).
85. Kahraman, S. et al. Impact of rHuEPO therapy initiation on soluble adhesion molecule levels in haemodialysis patients. Nephrology (Carlton) 10, 264-269 (2005).
86. Coleman, T. R. et al. Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc. Natl. Acad. Sci. USA 103, 5965-5970 (2006).
87. Vaziri, N. D. Mechanism of erythropoietin-induced hypertension. Am. J. Kidney Dis. 33, 821-828 (1999).
88. Coulon, P. J. et al. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure. Ren. Fail. 22, 435-444 (2000).
89. Szczech, L. A. et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 74, 791-798 (2008).
90. Solomon, S. D. et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N. Engl. J. Med. 363, 1146-1155 (2010).
91. Klarenbach, S. W. et al. Clinical practice guidelines for supplemental therapies and issues. Kidney Int. Suppl. 110, S19- S24 (2008).
92. Iglehart, J. K. Bundled payment for ESRD - including ESAs in Medicare's dialysis package. N. Engl. J. Med. 364, 593-595 (2011).
93. Pisoni, R. L. et al. The DOPPS practice monitor for US dialysis care: Trends through August 2011. Am. J. Kidney Dis. 60, 160-165 (2012).
94. Coyne, D. W. et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J. Am. Soc. Nephrol. 18, 975-984 (2007).
95. Kapoian, T. et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J. Am. Soc. Nephrol. 19, 372-379 (2008).
96. Coyne, D. W. It's time to compare anemia management strategies in hemodialysis. Clin. J. Am. Soc. Nephrol. 5, 740-742 (2010).
97. Feldman, H. I. et al. Administration of parenteral iron and mortality among hemodialysis patients. J. Am. Soc. Nephrol. 15, 1623-1632 (2004).
98. Vaziri, N. D. Understanding iron: Promoting its safe use in CKD patients. Am. J. Kidney Dis. http://dx.doi.org/10.1053/j.ajkd.2012.10.027.
99. Kalantar-Zadeh, K. et al. The fascinating but deceptive ferritin: To measure it or not to measure it in chronic kidney disease? Clin. J. Am. Soc. Nephrol. 1 (Suppl. 1), S9- S18 (2006).
100. Cavanese, C. et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int. 65, 1091-1098 (2004).
101. Ferrari, P. et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 6, 77-83 (2011).
102. Rostocker, G. et al. Hemodialysis-associated hemosiderosis in the era of erythropoisis-stimulating agents. Am. J. Med. 125, 991-999 (2012).
103. Kalantar-Zadeh, K., Kalantar-Zadeh, K. & Lee, G. H. The fascinating but deceptive ferritin: To measure it or not to measure it in chronic kidney disease? Clin. J. Am. Soc. Nephrol. 1 (Suppl. 1), S9- S18 (2006).
104. Locatelli, F. & Del Vecchio, L. New erythropoiesis-stimulating agents and new iron formulations. Contrib. Nephrol. 171, 255-260 (2011).
105. Barraclough, K. A. et al. A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial. Nephrol. Dial. Transplant. 27, 4146-4153 (2012).
106. Hörl, W. H. Clinical aspects of iron use in the anemia of kidney disease. J. Am. Soc. Nephrol. 18, 382-393 (2007).
107. Bennett, C. L. et al. A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: A report from the southern network on adverse reactions (SONAR). Semin. Thromb. Hemost. 38, 783-796 (2012).